Medicare's first drug negotiation list likely to fuel public pricing discussions for pharma marketers
Who’s on the list? That’s the question many in the pharma industry are asking today about CMS releasing the names of the first 10 drugs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
